

The Final Frontier: Venoms, Toxins and Antibodies

Wendye Robbins, MD

For more information, review the following articles:

- Bhattacharya, A., et al. (2009). Sodium channel blockers for the treatment of neuropathic pain. *Neurotherapeutics: The journal of the American Society for Experimental NeuroTherapeutics*, 6, 663-678.
- Diener, H.C., et al. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia: An International Journal of Headache*, 30(7), 804-814.
- Han, T.H., et al. (2010). Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults. *The Journal of Clinical Pharmacology*, 50, 1367-1376.
- Hoffman, J. and Peter J. Goadsby (2012). New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. *Current Treatment Options in Neurology*, 14, 50-59.
- Williams, J.A., et al. (2008). Ziconotide: An update and review. *Expert Opinion on Pharmacotherapy*, 9(9), 1575-1583.
- Zhang, L., et al. Alpha-cobratoxin inhibits T-type calcium currents through muscarinic M4 receptor and G_o-protein $\beta\gamma$ subunits-dependent protein kinase A pathway in dorsal root ganglion neurons. *Neuropharmacology*, 62, 1062-1072.